Benzenesulfonamide as a novel, pharmaceutical small molecule inhibitor on Aβ gene expression and oxidative stress in Alzheimer's Wistar rats

  • Biochem Biophys Res Commun. 2023 Sep 24:674:154-161. doi: 10.1016/j.bbrc.2023.06.063.
Mahshid Hesar Shourkabi  1 ,  Maryam Ghobeh  2 ,  Hanieh Jafary  1
Affiliations
  • 1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
  • 2. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran. Electronic address: [email protected].
PMID: 37421923 DOI: 10.1016/j.bbrc.2023.06.063
Abstract

Alzheimer's disease (AD) is the most prevalent acute neurodegenerative disease described by memory loss and Other cognitive functions. Benzenesulfonamide, a novel, potent, and small organic molecule, was synthesized to investigate its effects on the levels of oxidative biomarkers (GPx, ROS, and MDA) and expression of beta-amyloid peptides (Aβ40 and Aβ42) in the pathology of AD. The results were compared with the rivastigmine drug. Applying benzenesulfonamide to Alzheimer's-induced Wistar rats showed a significant increase in the level of oxidative biomarkers (GPx, ROS, and MDA) in both the brain and blood serum as well as amyloid-β40 and 42 gene expressions. Therefore, benzenesulfonamide could be considered a novel therapeutic agent against AD.

Keywords
Alzheimer's disease; Amyloid-β; Aβ gene expression; Benzenesulfonamide; Oxidative stress.
Products